rucaparib,nivolumab
clovis oncology,bms
['rucaparib', 'ovarian', 'athena-mono', 'gyn']
the athena-mono trial showed a significant improvement in pfs when patients with platinum-sensitive ovarian cancer were treated with maintenance rucaparib vs placebo in the first-line setting, regardless of hrd status. #gyncsm #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.